Back to News
Apr 29, 2026 4:01 PM

Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer Inc. (NYSE:PFE) on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab).

Multiple myeloma is an aggressive form of blood cancer that affects plasma cells made in the bone marrow.

It is the second most common type of blood cancer worldwide, with over 36,000 new cases each year in the U.S. and over 187,000 globally.

Read Also:

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Pfizer ELREXFIO Phase 3 Results

Pfizer announced topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO, a treatment for multiple myeloma, which is currently approved in over 35 countries.

The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression‑free survival ...